Wikipedia -WSS

Wikipedia

author：entertainment 2025-09-27 09:57:55 - browse：13

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into the fast-growing field of using targeted doses of radiation to treat cancer.

RayzeBio, which raised about $350 million in a September initial public offering, is working in radiopharmaceuticals, which pair the tumor-killing power of radiation with the precision of targeted cancer therapies. The company is currently running a pivotal trial of its most advanced drug, RYZ101, in neuroendocrine cancer and has a pipeline of treatments for kidney, liver, and other cancers.

Bristol Myers will pay $62.50 in cash per share of RayzeBio, a roughly 115% premium to the company’s recent trading and more than triple the company’s IPO price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Surge of respiratory disease in China has likely explanation

WSS

Medicare Advantage enrollment hits roughly 33.4 million

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Ukraine seeks to reclaim its role as a hub for clinical trials

FDA warns medical device makers about rise in fabricated data

Secretariat’s lessons for human medicine

Gain of function research would be limited under House proposal

explore

Wikipedia

knowledge

Malaria cases in Florida and Texas: Here’s what you need to know

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

The cancer drug shortage isn’t new — and neither are the solutions

Weight loss drug costs may need more research, senator suggests

Psychedelics group wrestles with new pharma identity

Surge of respiratory disease in China has likely explanation

Hepatitis C has a cure — but many Americans still lack access to it

NYU radiologists take on the challenge of expensive MRI machines

Duchenne breakthrough therapy leaves behind pioneering families

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

explore

FDA's Woodcock to retire early next year

New study raises questions about niacin and heart health

Poor hospice wound care hurts patients and families

Secretariat’s lessons for human medicine

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Wikipedia

hotspot

hotspot

leisure time